MATN2

Across TCGA pan-cancer cohorts, MATN2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MATN2 data layer compared with 21 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MATN2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MATN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where MATN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.220	0.726	<.001	34	view →
CCRCC	DFS	Median	IV	0.220	0.781	.017	16	view →
HNSC	OS	Tertile	IV	0.684	0.953	.016	11	view →
PDAC	OS	Quartile	III,IV	0.965	0.388	.016	5	view →
LSCC	OS	Median	II,III,IV	0.810	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MATN2–LUAD (DFS)

Open the LUAD breakdown →